News >

Bayer, Loxo to Collaborate on Larotrectinib

Jason Harris
Published: Tuesday, Nov 14, 2017

Przemyslaw W. Twardowski, MD

Przemyslaw W. Twardowski, MD
Bayer and Loxo Oncology have entered into a partnership to develop and market larotrectinib (LOXO-101) and LOXO-195 in the United States and worldwide. Both agents are investigational tropomyosin receptor kinase (TRK) inhibitors.

kinase point mutations. LOXO-195 was designed to treat these new point mutations and induce a new response.
Hyman DM, Laetsch TW, Kummar S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol. 2017;35 (suppl; abstr LBA2501).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication